Compare ZSQR & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZSQR | SPRY |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 697.4M | 796.4M |
| IPO Year | 2020 | 2020 |
| Metric | ZSQR | SPRY |
|---|---|---|
| Price | $7.83 | $8.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $40.00 |
| AVG Volume (30 Days) | 992.3K | ★ 1.9M |
| Earning Date | N/A | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $84,278,000.00 |
| Revenue This Year | N/A | $87.40 |
| Revenue Next Year | N/A | $81.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.94 | $6.66 |
| 52 Week High | $16.62 | $18.63 |
| Indicator | ZSQR | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 21.61 | 42.07 |
| Support Level | N/A | $7.41 |
| Resistance Level | N/A | $8.61 |
| Average True Range (ATR) | 1.76 | 0.58 |
| MACD | -0.60 | -0.16 |
| Stochastic Oscillator | 7.23 | 16.27 |
Z Squared Inc is a computing infrastructure company operating computing equipment and expanding into AI infrastructure. The Company's idea is to build on three principles: guide with power by acquiring operating sites where power is already flowing; build for AI workloads by converting that capacity into AI-ready colocation where the customer brings the compute and runs what it needs; and scale with discipline by deploying conversion capital site by site, against signed contracts and operational readiness.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.